HER2(ヒト上皮成長因子受容体2)阻害剤の世界市場2019-2023

◆英語タイトル:HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31894
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年8月28日
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、HER2(ヒト上皮成長因子受容体2)阻害剤の世界市場について調べ、HER2(ヒト上皮成長因子受容体2)阻害剤の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、HER2(ヒト上皮成長因子受容体2)阻害剤の市場規模をセグメンテーション別(製品別(単独療法、併用療法)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はHER2(ヒト上皮成長因子受容体2)阻害剤の世界市場規模が2019-2023期間中に年平均9%成長すると予測しています。
・サマリー
・レポートの範囲
・HER2(ヒト上皮成長因子受容体2)阻害剤の市場状況
・HER2(ヒト上皮成長因子受容体2)阻害剤の市場規模
・HER2(ヒト上皮成長因子受容体2)阻害剤の市場予測
・HER2(ヒト上皮成長因子受容体2)阻害剤の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(単独療法、併用療法)
・HER2(ヒト上皮成長因子受容体2)阻害剤の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: About this market
Technavio’s HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy. Our analysis also considers the sales of HER2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the presence of blockbuster drugs and fewer side-effects will play a significant role in the monotherapy segment to maintain its market position. Also, our global HER2 inhibitors market report looks at factors such as the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer. However, uncertainties in the introduction of Herceptin biosimilars, availability of alternative treatment options, and side effects of HER2 inhibitors may hamper the growth of the HER2 inhibitors industry over the forecast period.

Global HER2 Inhibitors Market: Overview

High prevalence of breast cancer and gastric cancer
HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. Owing to the overexpression of HER2, the prevalence of several cancers including breast cancer, gastric and ovarian cancer is increasing. As there is a significant unmet need for effective HER2 inhibitors with fewer side-effects, pharmaceutical companies have significant scope for growth. This will lead to the expansion of the global HER2 inhibitors market at a CAGR of almost 9% during the forecast period.

Patient assistance programs
HER2 inhibitors are available at high costs, making it difficult for patients to purchase them. Thus, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden, thus increasing patient adherence to HER2 inhibitors. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global HER2 inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global HER2 inhibitors market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 inhibitors manufacturers, that include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc.

Also, the HER2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Monotherapy – Market size and forecast 2018-2023
• Combination therapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Patient assistance programs
• Introduction of new diagnostics for breast cancer
• Strategic alliances
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Puma Biotechnology, Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Blockbuster drug sales for last three years
Exhibit 22: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Sales of PERJETA for last three years
Exhibit 25: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Effect on Herceptin sales after launch of biosimilars
Exhibit 45: Examples of available Herceptin biosimilars
Exhibit 46: Side effects associated with HER2 inhibitors
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Approximate cost of HER2 inhibitors
Exhibit 49: Examples of recently approved diagnostics for breast cancer
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 56: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 57: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 58: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 59: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 60: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 61: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 62: Merck & Co. Inc. – Vendor overview
Exhibit 63: Merck & Co. Inc. – Business segments
Exhibit 64: Merck & Co. Inc. – Organizational developments
Exhibit 65: Merck & Co. Inc. – Geographic focus
Exhibit 66: Merck & Co. Inc. – Segment focus
Exhibit 67: Merck & Co. Inc. – Key offerings
Exhibit 68: Merck & Co. Inc. – Key customers
Exhibit 69: Novartis AG – Vendor overview
Exhibit 70: Novartis AG – Business segments
Exhibit 71: Novartis AG – Organizational developments
Exhibit 72: Novartis AG – Geographic focus
Exhibit 73: Novartis AG – Segment focus
Exhibit 74: Novartis AG – Key offerings
Exhibit 75: Novartis AG – Key customers
Exhibit 76: Pfizer Inc. – Vendor overview
Exhibit 77: Pfizer Inc. – Business segments
Exhibit 78: Pfizer Inc. – Organizational developments
Exhibit 79: Pfizer Inc. – Geographic focus
Exhibit 80: Pfizer Inc. – Segment focus
Exhibit 81: Pfizer Inc. – Key offerings
Exhibit 82: Pfizer Inc. – Key customers
Exhibit 83: Puma Biotechnology Inc. – Vendor overview
Exhibit 84: Puma Biotechnology Inc. – Business segments
Exhibit 85: Puma Biotechnology Inc. – Organizational developments
Exhibit 86: Puma Biotechnology Inc. – Key offerings
Exhibit 87: Puma Biotechnology Inc. – Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors



【掲載企業】

F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Puma Biotechnology Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[HER2(ヒト上皮成長因子受容体2)阻害剤の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆